Overview

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle formulations
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
LEO Pharma